Showing results (1-10 of 574) with videos related to
Sort By:
Pageof 58
The Lancet. Oncology|June 7, 2017
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworksJoseph C Del Paggio, Richard Sullivan, Deborah Schrag, et al.JNCI Cancer Spectrum|July 31, 2019
Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research GroupsJoseph C Del Paggio, Sierra Cheng, Christopher M Booth, et al.JAMA Oncology|January 28, 2021
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income CountriesJ Connor Wells, Shubham Sharma, Joseph C Del Paggio, et al.Current Oncology (Toronto, Ont.)|April 21, 2022
Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research ActivityJ Connor Wells, Adam Fundytus, Shubham Sharma, et al.The Lancet. Oncology|July 13, 2019
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysisJoseph C Del Paggio, Ian F TannockJAMA Oncology|March 25, 2021
Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJoseph C Del Paggio, John S Berry, Wilma M Hopman, et al.The Lancet. Oncology|March 28, 2024
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional studyJoseph C Del Paggio, Rohini Naipaul, Scott Gavura, et al.Internal Medicine Journal|May 16, 2017
Disturbances in blood flow and 'medicine's greatest imitator'Joseph C Del Paggio, Scott Bradshaw, Laura MarcotteCurrent Oncology (Toronto, Ont.)|April 30, 2021
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled TrialsShubham Sharma, J Connor Wells, Wilma M Hopman, et al.Journal of the National Cancer Institute|December 16, 2017
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug AdministrationAriadna Tibau, Consolación Molto, Alberto Ocana, et al.Pageof 58